Monitoring Report: Respiratory Viruses - November 2024 Data

Samuel Gratzl*, PhD

Brianna M Goodwin Cartwright*, MS

Patricia J Rodriguez, PhD, MPH

Duy Do, PhD

Nicholas L Stucky, MD, PhD

* Denotes co-first author
Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:
Dr Nicholas Stucky
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: nicholass@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through December 01, 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and December 01, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 743,860 hospitalizations of 684,266 unique patients who tested positive for a respiratory virus between October 01, 2019 and December 01, 2024.

Overall, the rate of hospitalizations associated with respiratory viruses increased throughout October and November 2024. Between the last week of October and the last week of November, there was a 58.8% increase in respiratory virus-associated hospitalizations. By the last week of November, respiratory virus-associated hospitalizations accounted for 3.0% of all hospitalizations, up from 1.9% in late October. In the population 0-4 years of age, RSV-associated hospitalizations more than doubled over the month (up to 5.1% of all hospitalizations in this population). Test positivity in this age group also increased by 100.9%. COVID-associated hospitalization also nearly doubled, now accounting for 2.1% of all hospitalizations in this age group. Within the population over 65 years old, hospitalizations associated with respiratory viruses also continue to increase and now account for 3.1% of all hospitalizations within this age group; RSV- and influenza-associated hospitalizations had the greatest increase in the last month for this population.

Discussion: These data highlight continued increases in RSV-associated hospitalizations overall, but specifically for a pediatric population. Similarly, the doubling of COVID-associated hospitalizations in this age group highlights the continued burden of respiratory viruses on pediatric populations. These trends emphasize the need for

continued surveillance and public health interventions, particularly in vulnerable populations such as young children and older adults. The data also suggests that while declines in certain respiratory viruses are encouraging, the rising activity of others warrants attention to mitigate further strain on healthcare systems.

Trends in surveillance

Overall population



	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
October 28, 2024	1.9%	0.9%	0.1%	0.0%	0.1%	0.2%	0.8%
November 25, 2024	3.0%	0.9%	0.5%	0.1%	0.1%	0.7%	1.0%
Change (percentage)	+58.8%	+9.1%	+271.7%	+172.7%	+39.7%	+217.4%	+32.1%
Difference (percentage points)	+1.1%	+0.1%	+0.3%	+0.1%	+0.0%	+0.5%	+0.3%



	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
October 28, 2024	4.4%	5.2%	2.5%	0.6%	3.5%	3.4%	21.0%
November 25, 2024	6.4%	4.9%	5.7%	1.4%	3.4%	8.8%	19.6%
Change (percentage)	+43.9%	-5.5%	+130.8%	+122.9%	-3.2%	+157.9%	-6.9%
Difference (percentage points)	+1.9%	-0.3%	+3.3%	+0.8%	-0.1%	+5.4%	-1.4%

In the week ending November 25, 2024, respiratory virus-associated hospitalizations accounted for 3.0% of all hospitalizations, a notable increase from 1.9% at the end of October (+58.8%). The most substantial increases in hospitalization rates were observed for influenza (+271.7%), RSV (+217.4%), and human metapneumovirus (HMPV) (+172.7%). Parainfluenza and rhinovirus hospitalizations showed moderate increases (+39.7% and +32.1%, respectively). COVID-associated hospitalization rates, however, remained relatively stable.

Test positivity for respiratory viruses increased by 43.9% across the month of November; rates increased from 4.4% during the last week of October to 6.4% during the last week of November. RSV test positivity experienced the greatest increase (+157.9%), followed by significant rises in influenza (+130.8%) and HMPV (+122.9%) test positivity. Conversely, COVID test positivity declined slightly (-5.5%), while parainfluenza and rhinovirus test positivity also showed minor decreases (-3.2% and -6.9%, respectively). Despite the decrease, rhinovirus remained the virus with the highest test positivity at 19.6%.

Infants and children (age 0-4)



	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
October 28, 2024	4.8%	1.1%	0.1%	0.0%	0.2%	2.3%	2.9%
November 25, 2024	7.9%	2.1%	0.2%	0.1%	0.3%	5.1%	3.2%
Change (percentage)	+65.2%	+94.1%	+192.6%	+338.9%	+41.1%	+123.5%	+8.7%
Difference (percentage points)	+3.1%	+1.0%	+0.2%	+0.1%	+0.1%	+2.8%	+0.3%



	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
October 28, 2024	9.5%	5.5%	2.8%	1.3%	9.5%	14.4%	46.5%
November 25, 2024	13.8%	6.3%	5.6%	2.8%	8.0%	28.9%	41.0%
Change (percentage)	+45.8%	+14.6%	+99.1%	+124.4%	-15.2%	+100.9%	-11.7%
Difference (percentage points)	+4.3%	+0.8%	+2.8%	+1.6%	-1.4%	+14.5%	-5.4%

In the population aged 0–4 years, respiratory virus-associated hospitalizations increased by 65.2% between October 28 and November 25, 2024. RSV-associated hospitalizations experienced a dramatic rise (+123.5%), now accounting for 5.1% of all hospitalizations within this age group. COVID-associated hospitalizations also saw a significant increase (+94.1%), while hospitalizations associated with HMPV surged by +338.9%, however they represent a low overall percent of the hospitalized population. Parainfluenza- and influenza-associated hospitalizations rose more modestly (+41.1% and +192.6%, respectively). Rhinovirus hospitalizations showed a smaller increase of +8.7%. By late November, 7.9% of all hospitalizations in this age group were associated with a respiratory virus.

The overall test positivity rate for respiratory viruses in this population increased by 45.8% throughout November; climbing from 9.5% at the end of October to 13.8% at the end of November. HMPV and RSV test positivity saw the largest increases (+124.4% and 100.9%, respectively), followed by a notable rise in influenza (+99.1%). COVID test positivity also increased slightly (+14.6%). However, parainfluenza and rhinovirus test positivity rates declined by 15.2% and 11.7%, respectively; rhinovirus positivity remaining high at 41.0% as of late November 2024. These trends underscore the growing burden of RSV and other respiratory viruses in this vulnerable age group.

Older adults (age 65 and over)



	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
October 28, 2024	2.0%	1.2%	0.1%	0.0%	0.1%	0.1%	0.5%
November 25, 2024	3.1%	1.2%	0.5%	0.1%	0.2%	0.4%	0.9%
Change (percentage)	+57.2%	+0.6%	+267.6%	+196.9%	+56.0%	+297.8%	+65.9%
Difference (percentage points)	+1.1%	+0.0%	+0.4%	+0.1%	+0.1%	+0.3%	+0.3%



	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
October 28, 2024	3.3%	6.7%	1.1%	0.4%	1.5%	0.7%	8.7%
November 25, 2024	3.9%	6.2%	2.7%	0.7%	1.7%	2.2%	9.2%
Change (percentage)	+19.5%	-6.6%	+156.1%	+50.8%	+9.1%	+211.6%	+5.2%
Difference (percentage points)	+0.6%	-0.4%	+1.7%	+0.2%	+0.1%	+1.5%	+0.5%

Among older adults (age 65 and over), hospitalizations associated with respiratory viruses increased by 57.2% throughout November. RSV-associated hospitalizations experienced the largest increase (+297.8%); although it still represents a low

percentage of the overall population hospitalized. There were also large increases in influenza-associated hospitalizations (+267.6%) and HMPV-associated hospitalizations (+196.9%). Parainfluenza and rhinovirus hospitalizations also increased, though to a lesser extent (+56.0% and +65.9%, respectively). COVID-associated hospitalizations remained stable. By late November, respiratory virus-associated hospitalizations accounted for 3.1% of all hospitalizations in this age group, with COVID and rhinovirus contributing 1.2% and 0.9%, respectively.

The overall test positivity rate for respiratory viruses rose by 19.5%, climbing from 3.3% on October 28 to 3.9% on November 25, 2024. RSV test positivity saw the most substantial increase (+211.6%), followed by significant rises in influenza (+156.1%) and HMPV (+50.8%) positivity rates. Parainfluenza and rhinovirus test positivity also increased slightly (+9.1% and +5.2%, respectively). However, COVID test positivity declined modestly (-6.6%), though it remained a significant contributor at 6.2%. Rhinovirus test positivity continued to be notable, increasing to 9.2% by late November 2024. These patterns highlight the evolving landscape of respiratory virus activity among older adults, with rising hospitalizations and test positivity for RSV and influenza warranting close attention.

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death especially in vulnerable populations, such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2019 and December 01, 2024 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on December 16, 2024 and included de-identified patient care data primarily located across ten states: New York, California, Florida, Illinois, Washington, Ohio, Virginia, North Carolina, Louisiana, and Arizona.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first

day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Test positivity rate analysis

Lab results with known results were summarized over time by virus. The positivity rate was calculated monthly as the number of positive lab results divided by the total number of lab results with known results in that month.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 743,860 hospitalizations of 684,266 unique patients (Table 1).

Table 1: Patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	91,467 (100.00%)	171,661 (100.00%)	177,438 (100.00%)	123,855 (100.00%)	109,948 (100.00%)	9,897 (100.00%)	684,266 (100.00%)
Age Group							
< 6 months	1,931 (2.11%)	1,590 (0.93%)	2,749 (1.55%)	3,445 (2.78%)	2,663 (2.42%)	319 (3.22%)	12,697 (1.86%)
6 - <12 months	892 (0.98%)	630 (0.37%)	1,262 (0.71%)	1,589 (1.28%)	1,352 (1.23%)	202 (2.04%)	5,927 (0.87%)
1 - <2 years	1,079 (1.18%)	1,022 (0.60%)	1,832 (1.03%)	2,159 (1.74%)	1,807 (1.64%)	324 (3.27%)	8,223 (1.20%)
2 - 4 years	1,336 (1.46%)	1,085 (0.63%)	2,580 (1.45%)	3,240 (2.62%)	2,298 (2.09%)	446 (4.51%)	10,985 (1.61%)
5 - 17 years	1,464 (1.60%)	1,862 (1.08%)	3,190 (1.80%)	3,593 (2.90%)	3,155 (2.87%)	589 (5.95%)	13,853 (2.02%)
18 - 49 years	19,064 (20.84%)	38,968 (22.70%)	37,001 (20.85%)	16,993 (13.72%)	14,561 (13.24%)	1,415 (14.30%)	128,002 (18.71%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
50 - 64 years	21,723 (23.75%)	42,994 (25.05%)	36,023 (20.30%)	19,273 (15.56%)	17,614 (16.02%)	1,509 (15.25%)	139,136 (20.33%)
65 - 74 years	17,758 (19.41%)	35,496 (20.68%)	35,515 (20.02%)	24,151 (19.50%)	21,821 (19.85%)	1,744 (17.62%)	136,485 (19.95%)
75 - 84 years	16,002 (17.49%)	30,464 (17.75%)	34,756 (19.59%)	28,561 (23.06%)	26,289 (23.91%)	1,999 (20.20%)	138,071 (20.18%)
85+ years	10,218 (11.17%)	17,550 (10.22%)	22,530 (12.70%)	20,851 (16.84%)	18,388 (16.72%)	1,350 (13.64%)	90,887 (13.28%)
Sex							
Female	45,543 (49.79%)	83,274 (48.51%)	90,604 (51.06%)	64,664 (52.21%)	57,214 (52.04%)	5,043 (50.95%)	346,342 (50.62%)
Male	44,893 (49.08%)	86,736 (50.53%)	85,150 (47.99%)	58,188 (46.98%)	51,587 (46.92%)	4,734 (47.83%)	331,288 (48.42%)
Other	0	3 (0.00%)	2 (0.00%)	4 (0.00%)	0	0	9 (0.00%)
Unknown	1,031 (1.13%)	1,648 (0.96%)	1,682 (0.95%)	999 (0.81%)	1,147 (1.04%)	120 (1.21%)	6,627 (0.97%)
Race							
White	50,381 (55.08%)	110,027 (64.10%)	119,714 (67.47%)	83,109 (67.10%)	72,237 (65.70%)	6,165 (62.29%)	441,633 (64.54%)
Black or African American	13,690 (14.97%)	20,463 (11.92%)	20,508 (11.56%)	13,464 (10.87%)	13,111 (11.92%)	1,405 (14.20%)	82,641 (12.08%)
Asian	2,941 (3.22%)	4,323 (2.52%)	4,350 (2.45%)	4,132 (3.34%)	3,284 (2.99%)	321 (3.24%)	19,351 (2.83%)
Native Hawaiian or Other Pacific Islander	560 (0.61%)	890 (0.52%)	974 (0.55%)	659 (0.53%)	633 (0.58%)	80 (0.81%)	3,796 (0.55%)
American Indian or Alaska Native	595 (0.65%)	1,038 (0.60%)	1,100 (0.62%)	814 (0.66%)	652 (0.59%)	75 (0.76%)	4,274 (0.62%)
Other Race	8,239 (9.01%)	12,314 (7.17%)	10,288 (5.80%)	8,392 (6.78%)	7,295 (6.63%)	852 (8.61%)	47,380 (6.92%)
Unknown	15,061 (16.47%)	22,606 (13.17%)	20,504 (11.56%)	13,285 (10.73%)	12,736 (11.58%)	999 (10.09%)	85,191 (12.45%)
Ethnicity							
Hispanic or Latino	12,786 (13.98%)	19,842 (11.56%)	16,435 (9.26%)	12,961 (10.46%)	12,547 (11.41%)	1,359 (13.73%)	75,930 (11.10%)
Not Hispanic or Latino	62,620 (68.46%)	126,547 (73.72%)	139,612 (78.68%)	97,542 (78.75%)	87,179 (79.29%)	7,870 (79.52%)	521,370 (76.19%)
Unknown	16,061 (17.56%)	25,272 (14.72%)	21,391 (12.06%)	13,352 (10.78%)	10,222 (9.30%)	668 (6.75%)	86,966 (12.71%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Virus							
COVID	59,139 (64.66%)	160,599 (93.56%)	153,936 (86.75%)	74,960 (60.52%)	59,359 (53.99%)	4,450 (44.96%)	512,443 (74.89%)
HMPV	2,619 (2.86%)	82 (0.05%)	2,316 (1.31%)	3,993 (3.22%)	3,252 (2.96%)	132 (1.33%)	12,394 (1.81%)
RSV	6,072 (6.64%)	2,206 (1.29%)	4,449 (2.51%)	8,161 (6.59%)	9,720 (8.84%)	947 (9.57%)	31,555 (4.61%)
influenza	13,946 (15.25%)	392 (0.23%)	4,701 (2.65%)	16,974 (13.70%)	19,492 (17.73%)	822 (8.31%)	56,327 (8.23%)
parainfluenza	1,414 (1.55%)	1,477 (0.86%)	2,378 (1.34%)	4,324 (3.49%)	3,641 (3.31%)	425 (4.29%)	13,659 (2.00%)
rhinovirus	8,277 (9.05%)	6,905 (4.02%)	9,658 (5.44%)	15,443 (12.47%)	14,484 (13.17%)	3,121 (31.53%)	57,888 (8.46%)
Comorbidity							
Asthma	8,523 (9.32%)	13,761 (8.02%)	17,149 (9.66%)	14,637 (11.82%)	14,273 (12.98%)	1,517 (15.33%)	69,860 (10.21%)
Chronic Lung Disease	6,178 (6.75%)	10,661 (6.21%)	11,680 (6.58%)	9,180 (7.41%)	8,930 (8.12%)	864 (8.73%)	47,493 (6.94%)
Chronic Obstructive Pulmonary Disease	11,516 (12.59%)	18,414 (10.73%)	25,613 (14.43%)	21,249 (17.16%)	20,580 (18.72%)	1,873 (18.92%)	99,245 (14.50%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019



Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019



Test positivity rate over time

We included 53,814,780 lab results with known results of which 5,116,644 were positive. The test positivity rate is shown in Figure 3.



Figure 3: Weekly test positivity rate since October 2019

COVID-19

Our COVID study population consists of 533,133 hospitalizations of 512,443 unique patients (Table 2).

Table 2: COVID patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	59,139 (100.00%)	160,599 (100.00%)	153,936 (100.00%)	74,960 (100.00%)	59,359 (100.00%)	4,450 (100.00%)	512,443 (100.00%)
Age Group							
< 6 months	117 (0.20%)	336 (0.21%)	814 (0.53%)	440 (0.59%)	394 (0.66%)	56 (1.26%)	2,157 (0.42%)
6 - <12 months	43 (0.07%)	64 (0.04%)	290 (0.19%)	227 (0.30%)	236 (0.40%)	45 (1.01%)	905 (0.18%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
1 - <2 years	62 (0.10%)	109 (0.07%)	296 (0.19%)	204 (0.27%)	278 (0.47%)	97 (2.18%)	1,046 (0.20%)
2 - 4 years	106 (0.18%)	117 (0.07%)	424 (0.28%)	270 (0.36%)	318 (0.54%)	121 (2.72%)	1,356 (0.26%)
5 - 17 years	366 (0.62%)	930 (0.58%)	1,411 (0.92%)	586 (0.78%)	658 (1.11%)	202 (4.54%)	4,153 (0.81%)
18 - 49 years	14,033 (23.73%)	37,147 (23.13%)	33,696 (21.89%)	9,731 (12.98%)	6,419 (10.81%)	402 (9.03%)	101,428 (19.79%)
50 - 64 years	15,247 (25.78%)	41,430 (25.80%)	32,735 (21.27%)	11,352 (15.14%)	8,532 (14.37%)	551 (12.38%)	109,847 (21.44%)
65 - 74 years	11,951 (20.21%)	34,185 (21.29%)	32,115 (20.86%)	15,817 (21.10%)	12,576 (21.19%)	861 (19.35%)	107,505 (20.98%)
75 - 84 years	10,641 (17.99%)	29,383 (18.30%)	31,643 (20.56%)	20,530 (27.39%)	17,234 (29.03%)	1,219 (27.39%)	110,650 (21.59%)
85+ years	6,573 (11.11%)	16,898 (10.52%)	20,512 (13.33%)	15,803 (21.08%)	12,714 (21.42%)	896 (20.13%)	73,396 (14.32%)
Sex							
Female	28,338 (47.92%)	77,707 (48.39%)	78,527 (51.01%)	38,675 (51.59%)	30,142 (50.78%)	2,237 (50.27%)	255,626 (49.88%)
Male	30,138 (50.96%)	81,324 (50.64%)	73,915 (48.02%)	35,648 (47.56%)	28,525 (48.06%)	2,146 (48.22%)	251,696 (49.12%)
Other	0	3 (0.00%)	2 (0.00%)	2 (0.00%)	0	0	7 (0.00%)
Unknown	663 (1.12%)	1,565 (0.97%)	1,492 (0.97%)	635 (0.85%)	692 (1.17%)	67 (1.51%)	5,114 (1.00%)
Race							
White	29,102 (49.21%)	103,368 (64.36%)	104,858 (68.12%)	52,185 (69.62%)	40,502 (68.23%)	2,960 (66.52%)	332,975 (64.98%)
Black or African American	9,828 (16.62%)	18,755 (11.68%)	17,425 (11.32%)	7,289 (9.72%)	6,228 (10.49%)	473 (10.63%)	59,998 (11.71%)
Asian	2,035 (3.44%)	3,968 (2.47%)	3,481 (2.26%)	2,275 (3.03%)	1,839 (3.10%)	176 (3.96%)	13,774 (2.69%)
Native Hawaiian or Other Pacific Islander	382 (0.65%)	824 (0.51%)	766 (0.50%)	296 (0.39%)	272 (0.46%)	18 (0.40%)	2,558 (0.50%)
American Indian or Alaska Native	387 (0.65%)	963 (0.60%)	928 (0.60%)	406 (0.54%)	331 (0.56%)	32 (0.72%)	3,047 (0.59%)
Other Race	6,185 (10.46%)	11,119 (6.92%)	8,186 (5.32%)	4,082 (5.45%)	3,096 (5.22%)	328 (7.37%)	32,996 (6.44%)
Unknown	11,220 (18.97%)	21,602 (13.45%)	18,292 (11.88%)	8,427 (11.24%)	7,091 (11.95%)	463 (10.40%)	67,095 (13.09%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Ethnicity							
Hispanic or Latino	9,840 (16.64%)	18,476 (11.50%)	13,455 (8.74%)	6,180 (8.24%)	5,358 (9.03%)	432 (9.71%)	53,741 (10.49%)
Not Hispanic or Latino	37,746 (63.83%)	117,974 (73.46%)	121,308 (78.80%)	59,942 (79.97%)	48,048 (80.94%)	3,652 (82.07%)	388,670 (75.85%)
Unknown	11,553 (19.54%)	24,149 (15.04%)	19,173 (12.46%)	8,838 (11.79%)	5,953 (10.03%)	366 (8.22%)	70,032 (13.67%)
Comorbidity							
Asthma	3,789 (6.41%)	12,102 (7.54%)	13,673 (8.88%)	7,289 (9.72%)	6,523 (10.99%)	568 (12.76%)	43,944 (8.58%)
Chronic Lung Disease	2,897 (4.90%)	9,848 (6.13%)	9,828 (6.38%)	5,241 (6.99%)	4,649 (7.83%)	354 (7.96%)	32,817 (6.40%)
Chronic Obstructive Pulmonary Disease	4,941 (8.35%)	16,823 (10.48%)	21,776 (14.15%)	12,599 (16.81%)	11,170 (18.82%)	886 (19.91%)	68,195 (13.31%)

Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 4. Figure 5 shows seasonal trends.

Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2019



Figure 5: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 30,084,227 COVID lab results with known results of which 3,476,603 were positive. The COVID test positivity rate is shown in Figure 6. Figure 7 shows yearly trends.

Figure 6: Weekly COVID test positivity rate since October 2019

Figure 7: Weekly COVID test positivity rate by season



Influenza

Our influenza study population consists of 65,752 hospitalizations of 56,327 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	13,946 (100.00%)	392 (100.00%)	4,701 (100.00%)	16,974 (100.00%)	19,492 (100.00%)	822 (100.00%)	56,327 (100.00%)
Age Group							
< 6 months	90 (0.65%)	2 (0.51%)	31 (0.66%)	86 (0.51%)	93 (0.48%)	2 (0.24%)	304 (0.54%)
6 - <12 months	69 (0.49%)	1 (0.26%)	17 (0.36%)	68 (0.40%)	53 (0.27%)	3 (0.36%)	211 (0.37%)
1 - <2 years	109 (0.78%)	0	33 (0.70%)	121 (0.71%)	88 (0.45%)	3 (0.36%)	354 (0.63%)
2 - 4 years	161 (1.15%)	2 (0.51%)	58 (1.23%)	262 (1.54%)	208 (1.07%)	9 (1.09%)	700 (1.24%)
5 - 17 years	345 (2.47%)	3 (0.77%)	180 (3.83%)	592 (3.49%)	545 (2.80%)	22 (2.68%)	1,687 (3.00%)
18 - 49 years	2,959 (21.22%)	120 (30.61%)	1,067 (22.70%)	3,334 (19.64%)	3,983 (20.43%)	171 (20.80%)	11,634 (20.65%)
50 - 64 years	3,473 (24.90%)	95 (24.23%)	849 (18.06%)	3,510 (20.68%)	4,316 (22.14%)	193 (23.48%)	12,436 (22.08%)
65 - 74 years	2,905 (20.83%)	68 (17.35%)	934 (19.87%)	3,649 (21.50%)	4,190 (21.50%)	167 (20.32%)	11,913 (21.15%)
75 - 84 years	2,382 (17.08%)	72 (18.37%)	928 (19.74%)	3,399 (20.02%)	3,894 (19.98%)	155 (18.86%)	10,830 (19.23%)
85+ years	1,453 (10.42%)	29 (7.40%)	604 (12.85%)	1,953 (11.51%)	2,122 (10.89%)	97 (11.80%)	6,258 (11.11%)
Sex							
Female	7,605 (54.53%)	243 (61.99%)	2,647 (56.31%)	9,465 (55.76%)	10,607 (54.42%)	465 (56.57%)	31,032 (55.09%)
Male	6,171 (44.25%)	144 (36.73%)	2,002 (42.59%)	7,382 (43.49%)	8,723 (44.75%)	350 (42.58%)	24,772 (43.98%)
Other	0	0	0	2 (0.01%)	0	0	2 (0.00%)
Unknown	170 (1.22%)	5 (1.28%)	52 (1.11%)	125 (0.74%)	162 (0.83%)	7 (0.85%)	521 (0.92%)
Race							
White	9,147 (65.59%)	257 (65.56%)	3,160 (67.22%)	11,271 (66.40%)	12,526 (64.26%)	489 (59.49%)	36,850 (65.42%)
Black or African American	1,853 (13.29%)	70 (17.86%)	643 (13.68%)	2,302 (13.56%)	2,914 (14.95%)	131 (15.94%)	7,913 (14.05%)
Asian	356 (2.55%)	4 (1.02%)	99 (2.11%)	444 (2.62%)	507 (2.60%)	19 (2.31%)	1,429 (2.54%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Native Hawaiian or Other Pacific Islander	67 (0.48%)	1 (0.26%)	40 (0.85%)	111 (0.65%)	149 (0.76%)	7 (0.85%)	375 (0.67%)
American Indian or Alaska Native	76 (0.54%)	2 (0.51%)	41 (0.87%)	149 (0.88%)	127 (0.65%)	7 (0.85%)	402 (0.71%)
Other Race	667 (4.78%)	13 (3.32%)	245 (5.21%)	1,085 (6.39%)	1,303 (6.68%)	80 (9.73%)	3,393 (6.02%)
Unknown	1,780 (12.76%)	45 (11.48%)	473 (10.06%)	1,612 (9.50%)	1,966 (10.09%)	89 (10.83%)	5,965 (10.59%)
Ethnicity							
Hispanic or Latino	1,229 (8.81%)	30 (7.65%)	476 (10.13%)	1,995 (11.75%)	2,415 (12.39%)	136 (16.55%)	6,281 (11.15%)
Not Hispanic or Latino	10,726 (76.91%)	311 (79.34%)	3,757 (79.92%)	13,451 (79.24%)	15,522 (79.63%)	633 (77.01%)	44,400 (78.83%)
Unknown	1,991 (14.28%)	51 (13.01%)	468 (9.96%)	1,528 (9.00%)	1,555 (7.98%)	53 (6.45%)	5,646 (10.02%)
Comorbidity							
Asthma	1,891 (13.56%)	36 (9.18%)	695 (14.78%)	2,554 (15.05%)	2,942 (15.09%)	129 (15.69%)	8,247 (14.64%)
Chronic Lung Disease	1,308 (9.38%)	24 (6.12%)	417 (8.87%)	1,489 (8.77%)	1,780 (9.13%)	71 (8.64%)	5,089 (9.03%)
Chronic Obstructive Pulmonary Disease	2,808 (20.13%)	60 (15.31%)	991 (21.08%)	3,549 (20.91%)	3,962 (20.33%)	149 (18.13%)	11,519 (20.45%)

Hospitalization rate over time

The rate of influenza-associated hospitalization is shown in Figure 8. Figure 9 shows seasonal trends.

Figure 8: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2019



Figure 9: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 13,058,249 influenza lab results with known results of which 998,055 were positive. The influenza test positivity rate is shown in Figure 10. Figure 11 shows yearly trends.

Figure 10: Weekly influenza test positivity rate since October 2019

Figure 11: Weekly influenza test positivity rate by season



Human metapneumovirus (HMPV)

Our HMPV study population consists of 17,028 hospitalizations of 12,394 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	2,619 (100.00%)	82 (100.00%)	2,316 (100.00%)	3,993 (100.00%)	3,252 (100.00%)	132 (100.00%)	12,394 (100.00%)
< 6 months	58 (2.21%)	2 (2.44%)	83 (3.58%)	162 (4.06%)	78 (2.40%)	1 (0.76%)	384 (3.10%)
6 - <12 months	66 (2.52%)	2 (2.44%)	92 (3.97%)	113 (2.83%)	90 (2.77%)	4 (3.03%)	367 (2.96%)
1 - <2 years	74 (2.83%)	9 (10.98%)	145 (6.26%)	154 (3.86%)	82 (2.52%)	3 (2.27%)	467 (3.77%)
2 - 4 years	82 (3.13%)	12 (14.63%)	207 (8.94%)	249 (6.24%)	133 (4.09%)	7 (5.30%)	690 (5.57%)
5 - 17 years	55 (2.10%)	0	109 (4.71%)	140 (3.51%)	96 (2.95%)	6 (4.55%)	406 (3.28%)
18 - 49 years	279 (10.65%)	13 (15.85%)	253 (10.92%)	415 (10.39%)	401 (12.33%)	16 (12.12%)	1,377 (11.11%)
50 - 64 years	530 (20.24%)	18 (21.95%)	395 (17.06%)	647 (16.20%)	563 (17.31%)	25 (18.94%)	2,178 (17.57%)
65 - 74 years	522 (19.93%)	8 (9.76%)	395 (17.06%)	763 (19.11%)	657 (20.20%)	22 (16.67%)	2,367 (19.10%)
75 - 84 years	557 (21.27%)	12 (14.63%)	405 (17.49%)	826 (20.69%)	712 (21.89%)	26 (19.70%)	2,538 (20.48%)
85+ years	396 (15.12%)	6 (7.32%)	232 (10.02%)	524 (13.12%)	440 (13.53%)	22 (16.67%)	1,620 (13.07%)
Sex							
Female	1,494 (57.04%)	39 (47.56%)	1,306 (56.39%)	2,306 (57.75%)	1,983 (60.98%)	66 (50.00%)	7,194 (58.04%)
Male	1,088 (41.54%)	41 (50.00%)	996 (43.01%)	1,667 (41.75%)	1,242 (38.19%)	63 (47.73%)	5,097 (41.12%)
Unknown	37 (1.41%)	2 (2.44%)	14 (0.60%)	20 (0.50%)	27 (0.83%)	3 (2.27%)	103 (0.83%)
Race							
White	1,964 (74.99%)	54 (65.85%)	1,681 (72.58%)	2,828 (70.82%)	2,157 (66.33%)	85 (64.39%)	8,769 (70.75%)
Black or African American	214 (8.17%)	8 (9.76%)	232 (10.02%)	349 (8.74%)	360 (11.07%)	17 (12.88%)	1,180 (9.52%)
Asian	47 (1.79%)	0	48 (2.07%)	116 (2.91%)	73 (2.24%)	7 (5.30%)	291 (2.35%)
Native Hawaiian or Other Pacific Islander	13 (0.50%)	0	15 (0.65%)	13 (0.33%)	8 (0.25%)	0	49 (0.40%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
American Indian or Alaska Native	17 (0.65%)	1 (1.22%)	12 (0.52%)	35 (0.88%)	18 (0.55%)	1 (0.76%)	84 (0.68%)
Other Race	106 (4.05%)	9 (10.98%)	123 (5.31%)	296 (7.41%)	259 (7.96%)	13 (9.85%)	806 (6.50%)
Unknown	258 (9.85%)	10 (12.20%)	205 (8.85%)	356 (8.92%)	377 (11.59%)	9 (6.82%)	1,215 (9.80%)
Ethnicity							
Hispanic or Latino	183 (6.99%)	17 (20.73%)	240 (10.36%)	557 (13.95%)	487 (14.98%)	30 (22.73%)	1,514 (12.22%)
Not Hispanic or Latino	2,108 (80.49%)	53 (64.63%)	1,848 (79.79%)	3,128 (78.34%)	2,498 (76.81%)	99 (75.00%)	9,734 (78.54%)
Unknown	328 (12.52%)	12 (14.63%)	228 (9.84%)	308 (7.71%)	267 (8.21%)	3 (2.27%)	1,146 (9.25%)
Comorbidity							
Asthma	398 (15.20%)	9 (10.98%)	338 (14.59%)	610 (15.28%)	505 (15.53%)	18 (13.64%)	1,878 (15.15%)
Chronic Lung Disease	349 (13.33%)	8 (9.76%)	257 (11.10%)	402 (10.07%)	305 (9.38%)	13 (9.85%)	1,334 (10.76%)
Chronic Obstructive Pulmonary Disease	606 (23.14%)	12 (14.63%)	468 (20.21%)	781 (19.56%)	616 (18.94%)	25 (18.94%)	2,508 (20.24%)

Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 12. Figure 13 shows seasonal trends.

Figure 12: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2019



Figure 13: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 1,761,077 HMPV lab results with known results of which 46,852 were positive. The HMPV test positivity rate is shown in Figure 14. Figure 15 shows yearly trends.

Figure 14: Weekly HMPV test positivity rate since October 2019

Figure 15: Weekly HMPV test positivity rate by season



Parainfluenza virus

Our parainfluenza study population consists of 16,736 hospitalizations of 13,659 unique patients (Table 5).

Table 5: Parainfluenza patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	1,414 (100.00%)	1,477 (100.00%)	2,378 (100.00%)	4,324 (100.00%)	3,641 (100.00%)	425 (100.00%)	13,659 (100.00%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Age Group							
< 6 months	82 (5.80%)	109 (7.38%)	145 (6.10%)	226 (5.23%)	134 (3.68%)	12 (2.82%)	708 (5.18%)
6 - <12 months	39 (2.76%)	78 (5.28%)	101 (4.25%)	155 (3.58%)	82 (2.25%)	6 (1.41%)	461 (3.38%)
1 - <2 years	63 (4.46%)	113 (7.65%)	125 (5.26%)	176 (4.07%)	140 (3.85%)	17 (4.00%)	634 (4.64%)
2 - 4 years	80 (5.66%)	118 (7.99%)	209 (8.79%)	272 (6.29%)	162 (4.45%)	28 (6.59%)	869 (6.36%)
5 - 17 years	67 (4.74%)	89 (6.03%)	125 (5.26%)	219 (5.06%)	132 (3.63%)	27 (6.35%)	659 (4.82%)
18 - 49 years	143 (10.11%)	187 (12.66%)	289 (12.15%)	478 (11.05%)	394 (10.82%)	61 (14.35%)	1,552 (11.36%)
50 - 64 years	252 (17.82%)	249 (16.86%)	395 (16.61%)	711 (16.44%)	654 (17.96%)	72 (16.94%)	2,333 (17.08%)
65 - 74 years	241 (17.04%)	221 (14.96%)	405 (17.03%)	738 (17.07%)	690 (18.95%)	90 (21.18%)	2,385 (17.46%)
75 - 84 years	251 (17.75%)	203 (13.74%)	337 (14.17%)	800 (18.50%)	777 (21.34%)	70 (16.47%)	2,438 (17.85%)
85+ years	196 (13.86%)	110 (7.45%)	247 (10.39%)	549 (12.70%)	476 (13.07%)	42 (9.88%)	1,620 (11.86%)
Sex							
Female	765 (54.10%)	757 (51.25%)	1,301 (54.71%)	2,315 (53.54%)	1,967 (54.02%)	246 (57.88%)	7,351 (53.82%)
Male	633 (44.77%)	707 (47.87%)	1,060 (44.58%)	1,971 (45.58%)	1,638 (44.99%)	174 (40.94%)	6,183 (45.27%)
Unknown	16 (1.13%)	13 (0.88%)	17 (0.71%)	38 (0.88%)	36 (0.99%)	5 (1.18%)	125 (0.92%)
Race							
White	950 (67.19%)	932 (63.10%)	1,494 (62.83%)	2,734 (63.23%)	2,297 (63.09%)	256 (60.24%)	8,663 (63.42%)
Black or African American	144 (10.18%)	199 (13.47%)	282 (11.86%)	481 (11.12%)	439 (12.06%)	68 (16.00%)	1,613 (11.81%)
Asian	56 (3.96%)	41 (2.78%)	95 (3.99%)	189 (4.37%)	103 (2.83%)	9 (2.12%)	493 (3.61%)
Native Hawaiian or Other Pacific Islander	13 (0.92%)	3 (0.20%)	13 (0.55%)	20 (0.46%)	27 (0.74%)	1 (0.24%)	77 (0.56%)
American Indian or Alaska Native	9 (0.64%)	13 (0.88%)	18 (0.76%)	38 (0.88%)	25 (0.69%)	2 (0.47%)	105 (0.77%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Other Race	89 (6.29%)	145 (9.82%)	230 (9.67%)	439 (10.15%)	333 (9.15%)	41 (9.65%)	1,277 (9.35%)
Unknown	153 (10.82%)	144 (9.75%)	246 (10.34%)	423 (9.78%)	417 (11.45%)	48 (11.29%)	1,431 (10.48%)
Ethnicity							
Hispanic or Latino	105 (7.43%)	157 (10.63%)	300 (12.62%)	570 (13.18%)	541 (14.86%)	67 (15.76%)	1,740 (12.74%)
Not Hispanic or Latino	1,124 (79.49%)	1,156 (78.27%)	1,824 (76.70%)	3,341 (77.27%)	2,815 (77.31%)	326 (76.71%)	10,586 (77.50%)
Unknown	185 (13.08%)	164 (11.10%)	254 (10.68%)	413 (9.55%)	285 (7.83%)	32 (7.53%)	1,333 (9.76%)
Comorbidity							
Asthma	224 (15.84%)	222 (15.03%)	356 (14.97%)	663 (15.33%)	561 (15.41%)	76 (17.88%)	2,102 (15.39%)
Chronic Lung Disease	179 (12.66%)	134 (9.07%)	245 (10.30%)	415 (9.60%)	402 (11.04%)	43 (10.12%)	1,418 (10.38%)
Chronic Obstructive Pulmonary Disease	317 (22.42%)	284 (19.23%)	473 (19.89%)	874 (20.21%)	826 (22.69%)	90 (21.18%)	2,864 (20.97%)

Hospitalization rate over time

The rate of parainfluenza-associated hospitalization is shown in Figure 16. Figure 17 shows seasonal trends.

Figure 16: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions since October 2019

Figure 17: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 1,849,240 parainfluenza lab results with known results of which 68,256 were positive. The parainfluenza test positivity rate is shown in Figure 18. Figure 19 shows yearly trends.

Figure 18: Weekly parainfluenza test positivity rate since October 2019

Figure 19: Weekly parainfluenza test positivity rate by season



Respiratory syncytial virus (RSV)

Our RSV study population consists of 39,559 hospitalizations of 31,555 unique patients (Table 6).

Table 6: RSV patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	6,072 (100.00%)	2,206 (100.00%)	4,449 (100.00%)	8,161 (100.00%)	9,720 (100.00%)	947 (100.00%)	31,555 (100.00%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Age Group							
< 6 months	1,068 (17.59%)	630 (28.56%)	873 (19.62%)	1,602 (19.63%)	1,205 (12.40%)	130 (13.73%)	5,508 (17.46%)
6 - <12 months	414 (6.82%)	178 (8.07%)	321 (7.22%)	556 (6.81%)	494 (5.08%)	81 (8.55%)	2,044 (6.48%)
1 - <2 years	375 (6.18%)	210 (9.52%)	383 (8.61%)	606 (7.43%)	504 (5.19%)	80 (8.45%)	2,158 (6.84%)
2 - 4 years	365 (6.01%)	176 (7.98%)	370 (8.32%)	730 (8.94%)	435 (4.48%)	97 (10.24%)	2,173 (6.89%)
5 - 17 years	104 (1.71%)	48 (2.18%)	123 (2.76%)	254 (3.11%)	226 (2.33%)	45 (4.75%)	800 (2.54%)
18 - 49 years	333 (5.48%)	182 (8.25%)	372 (8.36%)	589 (7.22%)	829 (8.53%)	96 (10.14%)	2,401 (7.61%)
50 - 64 years	727 (11.97%)	252 (11.42%)	512 (11.51%)	871 (10.67%)	1,370 (14.09%)	118 (12.46%)	3,850 (12.20%)
65 - 74 years	870 (14.33%)	231 (10.47%)	550 (12.36%)	1,052 (12.89%)	1,547 (15.92%)	122 (12.88%)	4,372 (13.86%)
75 - 84 years	1,028 (16.93%)	185 (8.39%)	569 (12.79%)	1,110 (13.60%)	1,770 (18.21%)	108 (11.40%)	4,770 (15.12%)
85+ years	788 (12.98%)	114 (5.17%)	376 (8.45%)	791 (9.69%)	1,340 (13.79%)	70 (7.39%)	3,479 (11.03%)
Sex							
Female	3,295 (54.27%)	1,159 (52.54%)	2,264 (50.89%)	4,309 (52.80%)	5,277 (54.29%)	491 (51.85%)	16,795 (53.22%)
Male	2,738 (45.09%)	1,039 (47.10%)	2,156 (48.46%)	3,788 (46.42%)	4,354 (44.79%)	451 (47.62%)	14,526 (46.03%)
Unknown	39 (0.64%)	8 (0.36%)	29 (0.65%)	64 (0.78%)	89 (0.92%)	5 (0.53%)	234 (0.74%)
Race							
White	3,955 (65.14%)	1,327 (60.15%)	2,883 (64.80%)	5,174 (63.40%)	6,312 (64.94%)	484 (51.11%)	20,135 (63.81%)
Black or African American	637 (10.49%)	382 (17.32%)	525 (11.80%)	857 (10.50%)	1,078 (11.09%)	184 (19.43%)	3,663 (11.61%)
Asian	183 (3.01%)	59 (2.67%)	191 (4.29%)	432 (5.29%)	352 (3.62%)	46 (4.86%)	1,263 (4.00%)
Native Hawaiian or Other Pacific Islander	30 (0.49%)	17 (0.77%)	74 (1.66%)	148 (1.81%)	108 (1.11%)	42 (4.44%)	419 (1.33%)
American Indian or Alaska Native	45 (0.74%)	16 (0.73%)	37 (0.83%)	64 (0.78%)	72 (0.74%)	7 (0.74%)	241 (0.76%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Other Race	521 (8.58%)	198 (8.98%)	340 (7.64%)	695 (8.52%)	657 (6.76%)	99 (10.45%)	2,510 (7.95%)
Unknown	701 (11.54%)	207 (9.38%)	399 (8.97%)	791 (9.69%)	1,141 (11.74%)	85 (8.98%)	3,324 (10.53%)
Ethnicity							
Hispanic or Latino	673 (11.08%)	292 (13.24%)	589 (13.24%)	1,213 (14.86%)	1,260 (12.96%)	174 (18.37%)	4,201 (13.31%)
Not Hispanic or Latino	4,515 (74.36%)	1,687 (76.47%)	3,473 (78.06%)	6,200 (75.97%)	7,557 (77.75%)	732 (77.30%)	24,164 (76.58%)
Unknown	884 (14.56%)	227 (10.29%)	387 (8.70%)	748 (9.17%)	903 (9.29%)	41 (4.33%)	3,190 (10.11%)
Comorbidity							
Asthma	777 (12.80%)	233 (10.56%)	546 (12.27%)	995 (12.19%)	1,305 (13.43%)	133 (14.04%)	3,989 (12.64%)
Chronic Lung Disease	491 (8.09%)	128 (5.80%)	284 (6.38%)	529 (6.48%)	743 (7.64%)	69 (7.29%)	2,244 (7.11%)
Chronic Obstructive Pulmonary Disease	1,149 (18.92%)	259 (11.74%)	682 (15.33%)	1,274 (15.61%)	1,831 (18.84%)	115 (12.14%)	5,310 (16.83%)

Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 20. Figure 21 shows seasonal trends.

Figure 20: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2019

Figure 21: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 5,382,899 RSV lab results with known results of which 252,029 were positive. The RSV test positivity rate is shown in Figure 22. Figure 23 shows yearly trends.

Figure 22: Weekly RSV test positivity rate since October 2019

Figure 23: Weekly RSV test positivity rate by season



Rhinovirus

Our rhinovirus study population consists of 71,652 hospitalizations of 57,888 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	8,277 (100.00%)	6,905 (100.00%)	9,658 (100.00%)	15,443 (100.00%)	14,484 (100.00%)	3,121 (100.00%)	57,888 (100.00%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Age Group							
< 6 months	516 (6.23%)	511 (7.40%)	803 (8.31%)	929 (6.02%)	759 (5.24%)	118 (3.78%)	3,636 (6.28%)
6 - <12 months	261 (3.15%)	307 (4.45%)	441 (4.57%)	470 (3.04%)	397 (2.74%)	63 (2.02%)	1,939 (3.35%)
1 - <2 years	396 (4.78%)	581 (8.41%)	850 (8.80%)	898 (5.81%)	715 (4.94%)	124 (3.97%)	3,564 (6.16%)
2 - 4 years	542 (6.55%)	660 (9.56%)	1,312 (13.58%)	1,457 (9.43%)	1,042 (7.19%)	184 (5.90%)	5,197 (8.98%)
5 - 17 years	527 (6.37%)	792 (11.47%)	1,242 (12.86%)	1,802 (11.67%)	1,498 (10.34%)	287 (9.20%)	6,148 (10.62%)
18 - 49 years	1,317 (15.91%)	1,319 (19.10%)	1,324 (13.71%)	2,446 (15.84%)	2,535 (17.50%)	669 (21.44%)	9,610 (16.60%)
50 - 64 years	1,494 (18.05%)	950 (13.76%)	1,137 (11.77%)	2,182 (14.13%)	2,179 (15.04%)	550 (17.62%)	8,492 (14.67%)
65 - 74 years	1,269 (15.33%)	783 (11.34%)	1,116 (11.56%)	2,132 (13.81%)	2,161 (14.92%)	482 (15.44%)	7,943 (13.72%)
75 - 84 years	1,143 (13.81%)	609 (8.82%)	874 (9.05%)	1,896 (12.28%)	1,902 (13.13%)	421 (13.49%)	6,845 (11.82%)
85+ years	812 (9.81%)	393 (5.69%)	559 (5.79%)	1,231 (7.97%)	1,296 (8.95%)	223 (7.15%)	4,514 (7.80%)
Sex							
Female	4,046 (48.88%)	3,369 (48.79%)	4,559 (47.20%)	7,594 (49.17%)	7,238 (49.97%)	1,538 (49.28%)	28,344 (48.96%)
Male	4,125 (49.84%)	3,481 (50.41%)	5,021 (51.99%)	7,732 (50.07%)	7,105 (49.05%)	1,550 (49.66%)	29,014 (50.12%)
Unknown	106 (1.28%)	55 (0.80%)	78 (0.81%)	117 (0.76%)	141 (0.97%)	33 (1.06%)	530 (0.92%)
Race							
White	5,263 (63.59%)	4,089 (59.22%)	5,638 (58.38%)	8,917 (57.74%)	8,443 (58.29%)	1,891 (60.59%)	34,241 (59.15%)
Black or African American	1,014 (12.25%)	1,049 (15.19%)	1,401 (14.51%)	2,186 (14.16%)	2,092 (14.44%)	532 (17.05%)	8,274 (14.29%)
Asian	264 (3.19%)	251 (3.64%)	436 (4.51%)	676 (4.38%)	410 (2.83%)	64 (2.05%)	2,101 (3.63%)
Native Hawaiian or Other Pacific Islander	55 (0.66%)	45 (0.65%)	66 (0.68%)	71 (0.46%)	69 (0.48%)	12 (0.38%)	318 (0.55%)
American Indian or Alaska Native	61 (0.74%)	43 (0.62%)	64 (0.66%)	122 (0.79%)	79 (0.55%)	26 (0.83%)	395 (0.68%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Other Race	671 (8.11%)	830 (12.02%)	1,164 (12.05%)	1,795 (11.62%)	1,647 (11.37%)	291 (9.32%)	6,398 (11.05%)
Unknown	949 (11.47%)	598 (8.66%)	889 (9.20%)	1,676 (10.85%)	1,744 (12.04%)	305 (9.77%)	6,161 (10.64%)
Ethnicity							
Hispanic or Latino	756 (9.13%)	870 (12.60%)	1,375 (14.24%)	2,446 (15.84%)	2,486 (17.16%)	520 (16.66%)	8,453 (14.60%)
Not Hispanic or Latino	6,401 (77.33%)	5,366 (77.71%)	7,402 (76.64%)	11,480 (74.34%)	10,739 (74.14%)	2,428 (77.80%)	43,816 (75.69%)
Unknown	1,120 (13.53%)	669 (9.69%)	881 (9.12%)	1,517 (9.82%)	1,259 (8.69%)	173 (5.54%)	5,619 (9.71%)
Comorbidity							
Asthma	1,444 (17.45%)	1,159 (16.78%)	1,541 (15.96%)	2,526 (16.36%)	2,437 (16.83%)	593 (19.00%)	9,700 (16.76%)
Chronic Lung Disease	954 (11.53%)	519 (7.52%)	649 (6.72%)	1,104 (7.15%)	1,051 (7.26%)	314 (10.06%)	4,591 (7.93%)
Chronic Obstructive Pulmonary Disease	1,695 (20.48%)	976 (14.13%)	1,223 (12.66%)	2,172 (14.06%)	2,175 (15.02%)	608 (19.48%)	8,849 (15.29%)

Hospitalization rate over time

The rate of rhinovirus-associated hospitalization is shown in Figure 24. Figure 25 shows seasonal trends.

Figure 24: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2019

Figure 25: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 1,679,088 rhinovirus lab results with known results of which 274,849 were positive. The rhinovirus test positivity rate is shown in Figure 26. Figure 27 shows yearly trends.

Figure 26: Weekly rhinovirus test positivity rate since October 2019

Figure 27: Weekly rhinovirus test positivity rate by season



Infants and children (age 0-4)

Our infants and children study population consists of 49,405 hospitalizations of 37,832 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	5,238 (100.00%)	4,327 (100.00%)	8,423 (100.00%)	10,433 (100.00%)	8,120 (100.00%)	1,291 (100.00%)	37,832 (100.00%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Age Group							
< 6 months	1,931 (36.87%)	1,590 (36.75%)	2,749 (32.64%)	3,445 (33.02%)	2,663 (32.80%)	319 (24.71%)	12,697 (33.56%)
6 - <12 months	892 (17.03%)	630 (14.56%)	1,262 (14.98%)	1,589 (15.23%)	1,352 (16.65%)	202 (15.65%)	5,927 (15.67%)
1 - <2 years	1,079 (20.60%)	1,022 (23.62%)	1,832 (21.75%)	2,159 (20.69%)	1,807 (22.25%)	324 (25.10%)	8,223 (21.74%)
2 - 4 years	1,336 (25.51%)	1,085 (25.08%)	2,580 (30.63%)	3,240 (31.06%)	2,298 (28.30%)	446 (34.55%)	10,985 (29.04%)
Sex							
Female	2,307 (44.04%)	1,814 (41.92%)	3,484 (41.36%)	4,516 (43.29%)	3,521 (43.36%)	533 (41.29%)	16,175 (42.75%)
Male	2,930 (55.94%)	2,512 (58.05%)	4,925 (58.47%)	5,908 (56.63%)	4,586 (56.48%)	757 (58.64%)	21,618 (57.14%)
Unknown	1 (0.02%)	1 (0.02%)	14 (0.17%)	9 (0.09%)	13 (0.16%)	1 (0.08%)	39 (0.10%)
Race							
White	2,620 (50.02%)	2,194 (50.70%)	4,245 (50.40%)	4,950 (47.45%)	3,769 (46.42%)	531 (41.13%)	18,309 (48.40%)
Black or African American	881 (16.82%)	786 (18.17%)	1,359 (16.13%)	1,567 (15.02%)	1,235 (15.21%)	238 (18.44%)	6,066 (16.03%)
Asian	316 (6.03%)	189 (4.37%)	515 (6.11%)	803 (7.70%)	490 (6.03%)	74 (5.73%)	2,387 (6.31%)
Native Hawaiian or Other Pacific Islander	87 (1.66%)	68 (1.57%)	170 (2.02%)	211 (2.02%)	196 (2.41%)	46 (3.56%)	778 (2.06%)
American Indian or Alaska Native	52 (0.99%)	33 (0.76%)	70 (0.83%)	116 (1.11%)	58 (0.71%)	8 (0.62%)	337 (0.89%)
Other Race	840 (16.04%)	733 (16.94%)	1,295 (15.37%)	1,656 (15.87%)	1,255 (15.46%)	254 (19.67%)	6,033 (15.95%)
Unknown	442 (8.44%)	324 (7.49%)	769 (9.13%)	1,130 (10.83%)	1,117 (13.76%)	140 (10.84%)	3,922 (10.37%)
Ethnicity							
Hispanic or Latino	1,097 (20.94%)	807 (18.65%)	1,678 (19.92%)	2,502 (23.98%)	1,980 (24.38%)	329 (25.48%)	8,393 (22.18%)
Not Hispanic or Latino	3,591 (68.56%)	3,198 (73.91%)	6,145 (72.96%)	7,109 (68.14%)	5,505 (67.80%)	882 (68.32%)	26,430 (69.86%)
Unknown	550 (10.50%)	322 (7.44%)	600 (7.12%)	822 (7.88%)	635 (7.82%)	80 (6.20%)	3,009 (7.95%)
Virus							

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
COVID	328 (6.26%)	626 (14.47%)	1,824 (21.65%)	1,141 (10.94%)	1,226 (15.10%)	319 (24.71%)	5,464 (14.44%)
HMPV	280 (5.35%)	25 (0.58%)	527 (6.26%)	678 (6.50%)	383 (4.72%)	15 (1.16%)	1,908 (5.04%)
RSV	2,222 (42.42%)	1,194 (27.59%)	1,947 (23.12%)	3,494 (33.49%)	2,638 (32.49%)	388 (30.05%)	11,883 (31.41%)
influenza	429 (8.19%)	5 (0.12%)	139 (1.65%)	537 (5.15%)	442 (5.44%)	17 (1.32%)	1,569 (4.15%)
parainfluenza	264 (5.04%)	418 (9.66%)	580 (6.89%)	829 (7.95%)	518 (6.38%)	63 (4.88%)	2,672 (7.06%)
rhinovirus	1,715 (32.74%)	2,059 (47.58%)	3,406 (40.44%)	3,754 (35.98%)	2,913 (35.87%)	489 (37.88%)	14,336 (37.89%)
Comorbidity							
Asthma	394 (7.52%)	298 (6.89%)	514 (6.10%)	684 (6.56%)	540 (6.65%)	121 (9.37%)	2,551 (6.74%)
Chronic Lung Disease	61 (1.16%)	26 (0.60%)	47 (0.56%)	66 (0.63%)	59 (0.73%)	7 (0.54%)	266 (0.70%)
Chronic Obstructive Pulmonary Disease	11 (0.21%)	4 (0.09%)	12 (0.14%)	13 (0.12%)	17 (0.21%)	0	57 (0.15%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 28. Figure 29 shows the same data stacked to represent the combined impact of the viruses.

Figure 28: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five



Figure 29: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five



Test positivity rate over time

We included 5,444,827 lab results with known results of infants and children under age five. Of those tests, 627,601 lab results were positive. The test positivity rate for infants and children under age five is shown in Figure 30.

Figure 30: Weekly test positivity rate since October 2019 for infants and children under five



Older adults (age 65 and over)

Our older adults study population consists of 393,316 hospitalizations of 365,443 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	43,978 (100.00%)	83,510 (100.00%)	92,801 (100.00%)	73,563 (100.00%)	66,498 (100.00%)	5,093 (100.00%)	365,443 (100.00%)
Age Group							
65 - 74 years	17,758 (40.38%)	35,496 (42.51%)	35,515 (38.27%)	24,151 (32.83%)	21,821 (32.81%)	1,744 (34.24%)	136,485 (37.35%)
75 - 84 years	16,002 (36.39%)	30,464 (36.48%)	34,756 (37.45%)	28,561 (38.83%)	26,289 (39.53%)	1,999 (39.25%)	138,071 (37.78%)
85+ years	10,218 (23.23%)	17,550 (21.02%)	22,530 (24.28%)	20,851 (28.34%)	18,388 (27.65%)	1,350 (26.51%)	90,887 (24.87%)
Sex							

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Female	22,305 (50.72%)	40,690 (48.72%)	46,528 (50.14%)	38,735 (52.66%)	34,854 (52.41%)	2,658 (52.19%)	185,770 (50.83%)
Male	21,472 (48.82%)	42,533 (50.93%)	45,911 (49.47%)	34,493 (46.89%)	31,191 (46.91%)	2,364 (46.42%)	177,964 (48.70%)
Unknown	201 (0.46%)	287 (0.34%)	362 (0.39%)	335 (0.46%)	453 (0.68%)	71 (1.39%)	1,709 (0.47%)
Race							
White	27,932 (63.51%)	60,521 (72.47%)	69,903 (75.33%)	55,275 (75.14%)	48,600 (73.08%)	3,738 (73.39%)	265,969 (72.78%)
Black or African American	4,886 (11.11%)	6,662 (7.98%)	7,106 (7.66%)	5,262 (7.15%)	5,381 (8.09%)	461 (9.05%)	29,758 (8.14%)
Asian	1,036 (2.36%)	1,544 (1.85%)	1,753 (1.89%)	1,941 (2.64%)	1,737 (2.61%)	141 (2.77%)	8,152 (2.23%)
Native Hawaiian or Other Pacific Islander	79 (0.18%)	138 (0.17%)	186 (0.20%)	166 (0.23%)	155 (0.23%)	9 (0.18%)	733 (0.20%)
American Indian or Alaska Native	128 (0.29%)	249 (0.30%)	317 (0.34%)	320 (0.44%)	275 (0.41%)	24 (0.47%)	1,313 (0.36%)
Other Race	2,004 (4.56%)	3,083 (3.69%)	2,818 (3.04%)	2,904 (3.95%)	2,816 (4.23%)	211 (4.14%)	13,836 (3.79%)
Unknown	7,913 (17.99%)	11,313 (13.55%)	10,718 (11.55%)	7,695 (10.46%)	7,534 (11.33%)	509 (9.99%)	45,682 (12.50%)
Ethnicity							
Hispanic or Latino	2,644 (6.01%)	4,493 (5.38%)	4,054 (4.37%)	4,167 (5.66%)	4,640 (6.98%)	391 (7.68%)	20,389 (5.58%)
Not Hispanic or Latino	32,027 (72.83%)	64,793 (77.59%)	75,880 (81.77%)	60,467 (82.20%)	55,000 (82.71%)	4,336 (85.14%)	292,503 (80.04%)
Unknown	9,307 (21.16%)	14,224 (17.03%)	12,867 (13.87%)	8,929 (12.14%)	6,858 (10.31%)	366 (7.19%)	52,551 (14.38%)
Virus							
COVID	29,165 (66.32%)	80,466 (96.35%)	84,270 (90.81%)	52,150 (70.89%)	42,524 (63.95%)	2,976 (58.43%)	291,551 (79.78%)
HMPV	1,475 (3.35%)	26 (0.03%)	1,032 (1.11%)	2,113 (2.87%)	1,809 (2.72%)	70 (1.37%)	6,525 (1.79%)
RSV	2,686 (6.11%)	530 (0.63%)	1,495 (1.61%)	2,953 (4.01%)	4,657 (7.00%)	300 (5.89%)	12,621 (3.45%)
influenza	6,740 (15.33%)	169 (0.20%)	2,466 (2.66%)	9,001 (12.24%)	10,206 (15.35%)	419 (8.23%)	29,001 (7.94%)
parainfluenza	688 (1.56%)	534 (0.64%)	989 (1.07%)	2,087 (2.84%)	1,943 (2.92%)	202 (3.97%)	6,443 (1.76%)

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
rhinovirus	3,224 (7.33%)	1,785 (2.14%)	2,549 (2.75%)	5,259 (7.15%)	5,359 (8.06%)	1,126 (22.11%)	19,302 (5.28%)
Comorbidity							
Asthma	3,671 (8.35%)	6,039 (7.23%)	7,865 (8.48%)	7,444 (10.12%)	7,301 (10.98%)	652 (12.80%)	32,972 (9.02%)
Chronic Lung Disease	3,392 (7.71%)	5,966 (7.14%)	7,092 (7.64%)	6,312 (8.58%)	6,064 (9.12%)	567 (11.13%)	29,393 (8.04%)
Chronic Obstructive Pulmonary Disease	8,152 (18.54%)	13,683 (16.38%)	18,922 (20.39%)	16,398 (22.29%)	15,917 (23.94%)	1,422 (27.92%)	74,494 (20.38%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in `Figure 31. Figure 32 shows the same data stacked to represent the combined impact of the viruses.

Figure 31: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older



Figure 32: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older



Test positivity rate over time

We included 15,969,736 lab results with known results of adults aged 65 and over. Of those tests, 1,132,850 lab results were positive. The test positivity rate for adults aged 65 and over is shown in Figure 33.

Figure 33: Weekly test positivity rate since October 2019 for adults 65 years or older



Discussion and conclusion

In the week ending November 25, 2024, overall respiratory virus-associated hospitalizations accounted for 3.0% of all hospitalizations, a notable increase from 1.9% at the end of October (+58.8%). The most substantial increases in hospitalization rates were observed for influenza (+271.7%), RSV (+217.4%), and human metapneumovirus (HMPV) (+172.7%). Parainfluenza and rhinovirus hospitalizations showed moderate increases (+39.7% and +32.1%, respectively). COVID-associated hospitalization rates, however, remained relatively stable. Test positivity for respiratory viruses increased by 43.9% across the month of November; rates increased from 4.4% during the last week of October to 6.4% during the last week of November. RSV test positivity experienced the greatest increase (+157.9%), followed by significant rises in influenza (+130.8%) and HMPV (+122.9%) test positivity. Conversely, COVID test positivity declined slightly (-5.5%), while parainfluenza and rhinovirus test positivity also showed minor decreases (-3.2% and -6.9%, respectively). Despite the decrease, rhinovirus remained the virus with the highest test positivity at 19.6%.

In the population aged 0–4 years, respiratory virus-associated hospitalizations increased by 65.2% between October 28 and November 25, 2024. RSV-associated hospitalizations experienced a dramatic rise (+123.5%), now accounting for 5.1% of all hospitalizations within this age group. COVID-associated hospitalizations also saw a significant increase (+94.1%), while hospitalizations associated with HMPV surged by +338.9%, however they represent a low overall percent of the hospitalized population.

Parainfluenza- and influenza-associated hospitalizations rose more modestly (+41.1% and +192.6%, respectively). Rhinovirus hospitalizations showed a smaller increase of +8.7%. By late November, 7.9% of all hospitalizations in this age group were associated with a respiratory virus. The overall test positivity rate for respiratory viruses in this population increased by 45.8% throughout November; climbing from 9.5% at the end of October to 13.8% at the end of November. HMPV and RSV test positivity saw the largest increases (+124.4% and 100.9%, respectively), followed by a notable rise in influenza (+99.1%). COVID test positivity also increased slightly (+14.6%). However, parainfluenza and rhinovirus test positivity rates declined by 15.2% and 11.7%, respectively; rhinovirus positivity remaining high at 41.0% as of late November 2024. These trends underscore the growing burden of RSV and other respiratory viruses in this vulnerable age group.

Among older adults (age 65 and over), hospitalizations associated with respiratory viruses increased by 57.2% throughout November. RSV-associated hospitalizations experienced the largest increase (+297.8%); although it still represents a low percentage of the overall population hospitalized. There were also large increases in influenza-associated hospitalizations (+267.6%) and HMPV-associated hospitalizations (+196.9%). Parainfluenza and rhinovirus hospitalizations also increased, though to a lesser extent (+56.0% and +65.9%, respectively). COVID-associated hospitalizations remained stable. By late November, respiratory virus-associated hospitalizations accounted for 3.1% of all hospitalizations in this age group, with COVID and rhinovirus contributing 1.2% and 0.9%, respectively. The overall test positivity rate for respiratory viruses rose by 19.5%, climbing from 3.3% on October 28 to 3.9% on November 25, 2024. RSV test positivity saw the most substantial increase (+211.6%), followed by significant rises in influenza (+156.1%) and HMPV (+50.8%) positivity rates. Parainfluenza and rhinovirus test positivity also increased slightly (+9.1% and +5.2%, respectively). However, COVID test positivity declined modestly (-6.6%), though it remained a significant contributor at 6.2%. Rhinovirus test positivity continued to be notable, increasing to 9.2% by late November 2024. These patterns highlight the evolving landscape of respiratory virus activity among older adults, with rising hospitalizations and test positivity for RSV and influenza warranting close attention.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed December 16, 2024. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to

the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. The Journal of Pediatrics, 137(6), 865-870. https://doi.org/10.1067/mpd.2000.110531

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. https://www.cdc.gov/flu/about/burden/past-seasons.html

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. https://www.cdc.gov/surveillance/nrevss/index.html

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. https://www.cdc.gov/rsv/research/rsv-net/dashboard.html

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., … Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620-e638. https://doi.org/10.1542/peds.2014-1666

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahon, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K

Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz225, https://doi.org/10.1093/ofid/ofz225

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57(8), 1069–1077. https://doi.org/10.1093/cid/cit471

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infectious Diseases, 4(1), ofw270. https://doi.org/10.1093/ofid/ofw270

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., ... Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. https://doi.org/10.1016/S0140-6736(17)30938-8

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023 Apr 6;41(15):2447-2455. https://doi.org/10.1016/j.vaccine.2023.02.038. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511-1518. https://doi.org/10.1093/cid/cix1060. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy